9 results
To identify and define characteristics of healthy lymph nodes and lymph nodes involved in different pulmonal diseases (lungcancer and sarcoidosis)
To establish in vivo CLE characteristics of Upper Urinary Tract Urothelial Carcinoma
To describe criteria on CLE-imaging of different entities (thoracic wall/ pleura/ fibrosis/ mediastinum) compared to histology.
The primary efficacy objectives for this study are as follows:* To evaluate the efficacy of etrolizumab (105 mg SC every 4 weeks [Q4W]) compared with placebo for the induction of remission as determined by the MCS at W14* To evaluate the efficacy of…
The objectives of this open-label extension safety monitoring (OLE-SM) study are as follows:Part 1 (Open-Label Extension; OLE)• To assess the long-term safety and efficacy of etrolizumab in patients eligible for Part 1 (OLE)Part 2 (Safety Monitoring…
The objectives of this open-label extension*safety monitoring (OLE-SM) study are as follows: Part 1 (Open-Label Extension; OLE) • To assess the long-term safety and efficacy of etrolizumab in patients eligible for Part 1 (OLE) Part 2 (Safety…
Induction Phase (IP)* To independently evaluate the efficacy of etrolizumab dose regimens compared with placebo in inducing clinical remission and endoscopic improvement at the end of the Induction Phase (Week 14)Maintenance Phase (MP)* To…
The primary efficacy objective for this study is as follows:* To evaluate the efficacy of etrolizumab (105 mg subcutaneous [SC] every 4 weeks [Q4W]) compared with infliximab in achieving both clinical response at Week (W) 10, and clinical remission…
Primary objectives: This study is two-fold and, therefore, has two primary objectives:1. Investigating the diagnostic accuracy of CLE (Cystoflex*F probe) during flexible cystoscopy for diagnosis and grading of urothelial carcinoma of the bladder.2.…